IBA Business Update – Third Quarter 2022

Group Overview

• Business operations continue to be strong, with good performance across all four business units
• Exceptional group order intake of EUR 260 million at 30 September for 2022 to date, compared to EUR 133 million for the first nine months of 2021, driven by strong performance across the business, particularly within Industrial Solutions
• Backlog remains high at EUR 1.2 billion and new tenders continue to progress internationally for all business units
• Strong balance sheet with (unaudited) net cash position of EUR 134 million (30 June 2022: 137 million) Olivier Legrain, Chief Executive Officer of IBA commented: “IBA has continued to see solid performance in the third quarter across all business units, both in terms of contract wins, technological advances and supported by targeted value driving acquisitions. We have been especially pleased to see continued momentum in Industrial Solutions, with the business unit passing a key milestone of EUR 100 million order intake to date this year. Within proton therapy we are seeing market dynamics shifting favorably with demand building in all regions globally and resulting in IBA winning strategically significant, high-value contracts. Looking ahead, whilst some challenges remain, the strategies and investments we are making are positively impacting and we are confident in the longer-term performance of the Group, underpinned by a strong balance sheet that we will continue to utilize for investment in future growth.”

Proton Therapy

• 24 projects ongoing in Proton Therapy, with nine Proteus®PLUS1 and 15 Proteus®ONE1 systems in progress
• An active global pipeline, highlighting the strength of proton therapy market across all geographies
• A total of 40 service contracts now generating recurring revenues globally
• IBA qualified as the only supplier for the second round of significant tender to provide ten proton therapy units across Spain
• Multi-year research collaboration signed with Fred Hutchinson Cancer Center and the University of Washington (UW), Seattle, for ConformalFLASH®2 Proton Therapy
• Collaboration agreement signed with Apollo Hospitals Enterprise Ltd (AHEL)
• The PROTECT-trial consortium enrolled the first patient in a trial investigating proton therapy in oesophageal cancer

1. Proteus®PLUS and Proteus®ONE are brand names of Proteus 235
2. ConformalFLASH® is a registered brand of IBA’s Proton FLASH irradiation solution currently under research and development phase.

Other Accelerators (RadioPharma, Industrial)

• Other Accelerators continued to perform strongly in Q3, with eight new systems sold in the period. A total of 29 systems have been sold in the first nine months of 2022, compared to 23 for the same period last year
• Exceptional performance by Industrial Solutions, with the business reaching the milestone of EUR 100 million order intake to date
• Collaboration deal agreed with Chengdu New Radiomedicine Technology Co., Ltd (CNRT) to install a Cyclone® IKON in Chengdu, Sichuan Province, China
• Agreement signed with NorthStar Medical Radioisotopes for two additional Rhodotron® electron beam accelerators for commercial production of radioisotopes
• Launched Pantera, a joint venture with SCK CEN to produce actinium-225, one of the most promising alpha-emitting radioisotopes to fight cancers
• Contract for the installation of an integrated radiopharmaceutical production facility in Georgia, signed post-period end
• Post-period, contract with Sweden Ghana Medical Centre signed for an IntegraLab® PLUS in Ghana